NervGen to restate previously filed financial statements for non-cash accounting adjustments
NGEN•NervGen will restate its audited fiscal 2025 and unaudited second-quarter 2026 financial statements. The adjustments are expected to reduce stock-based compensation expense, warrant liabilities and accumulated deficit, with no impact on cash, cash runway or business operations.
1. Expected adjustments
NervGen said it will revise its valuation of warrants and options, reducing stock-based compensation expense. The company said the adjustments have no impact on cash, cash runway or business operations.
2. Reporting schedule
NervGen said it remains on track to report third-quarter 2026 financial results.
